CD47 is a transmembrane protein a cell surface glycoprotein molecule belonging to the immunoglobulin superfamily that binds to a variety of proteins including integrins thrombospondin 1 and signal regulatory protein- (SIRP). In recent years accumulating data have demonstrated that the CD47-SIRPV2 axis is a key immune checkpoint in different cancers including hematological malignancies similar to PD-1/PD-L1 in solid tumors. CD47-SIRPV2 blockade has become a next-generation immune checkpoint blocking strategy for various malignancies after PD-1/PD-L1.